trial · primary record
Ifinatamab deruxtecan
Prostate Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1440 |
| Primary completion | 2031-01-06 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT06925737 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:16.974Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06925737
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ifinatamab Deruxtecan · compound